适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 15
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
Dosimetry of a novel amino acid PET tracer, [18F]FELPGlioblastomaCTIS2022-501696-91-00niversitair Ziekenhuis Gent10
进行中（未招募）
1 期
Kidney cancerMetastatic Clear Cell Renal Cell Carcinoma (ccRCC) or papillary renal cell carcinoma (pRCC) and with End-Stage Renal Disease (ESRD)MedDRA version: 21.1Level: PTClassification code: 10050513Term: Metastatic renal cell carcinoma Class: 100000004864MedDRA version: 22.0Level: HLTClassification code: 10038443Term: Renal failure and impairment Class: 10038359CTIS2023-505605-16-00Oncorena AB50
进行中（未招募）
1 期
A trial in healthy volunteers to study safety, tolerability, CS014-levels and effects in the body, after single and repeated doses of CS014, for the first time in humans.Cardiovascular diseaseCTIS2024-510878-24-00Cereno Scientific AB48
进行中（未招募）
1 期
A Phase 1/2, First-in-Human, Open-Label, Dose Escalation and Expansion Study of STAR0602, a Selective T Cell Receptor (TCR) - targeting, Bifunctional Antibody-fusion molecule, in Subjects with Unresectable, Locally Advanced, or Metastatic Solid Tumors that are Antigen-Rich (START-001)nresectable, Locally Advanced, or Metastatic Solid TumorsCTIS2023-505334-10-00Marengo Therapeutics Inc.271
进行中（未招募）
1 期
Phase 1/2 study testing for the first time in humans a novel drug, STAR0602, to selectively stimulate T cells for the treatment of subjects with advanced solid tumors that cannot be removed with surgery or has spread locally or to other parts of the body.CTIS2023-505334-10-01Marengo Therapeutics Inc.271